Form 4: Instil Bio Director R Kent Jr McGaughy Reports Acquisition of 6,500 Stock Options

Instil Bio, Inc. Director and 10% Owner R Kent Jr McGaughy reported the acquisition of 6,500 stock options with an exercise price of $26.75, vesting over 12 months or upon specific conditions.

Summary

• R Kent Jr McGaughy, a Director and 10% Owner of Instil Bio, Inc. (TIL), acquired 6,500 stock options.
• The transaction date for this acquisition was May 28, 2025.
• Each option has an exercise price of $26.75.
• The options will vest in 12 substantially equal monthly installments commencing June 28, 2025, subject to the Reporting Person's Continuous Service.
• Full vesting can also occur on the date of the next annual stockholder meeting (if not already vested), or upon the reporting person's death, Disability (as defined in the Plan), or a Change in Control (as defined in the Plan).
• The options expire on May 27, 2035.
• Following this reported transaction, R Kent Jr McGaughy beneficially owns 6,500 derivative securities.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive signal as it aligns their interests with shareholders and incentivizes long-term performance, though it's a routine compensation event rather than a major operational announcement.

Positives

• The acquisition of stock options by a director aligns their financial interests with those of shareholders, as the options gain value if the company's stock price increases.
• The vesting schedule incentivizes the director's long-term commitment and continuous service to Instil Bio.

Risks

• The value of the stock options is contingent on Instil Bio's common stock price exceeding the exercise price of $26.75; if the stock price remains below this level, the options may expire worthless.
• Vesting of the options is subject to the reporting person's continuous service, meaning unvested options could be forfeited if service terminates prematurely.

Future Outlook

This filing primarily reports an insider equity grant and does not provide a general future outlook for Instil Bio. However, the stock option grant incentivizes the director's long-term commitment and performance alignment with shareholder interests.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, including for companies like Instil Bio, to align the interests of board members with long-term shareholder value creation, especially given the long development cycles and high-risk nature of the sector.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The specific exercise price and vesting schedule would typically be benchmarked against peer companies of similar size and stage, though this document does not provide such comparative data.
• The vesting conditions, including accelerated vesting upon death, disability, or change in control, are also common provisions in equity incentive plans.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options become valuable only if the stock price increases.

Next Steps

• The acquired stock options will begin vesting in 12 substantially equal monthly installments commencing June 28, 2025.
• Any unvested portion of the option will vest in full on the date of the next annual stockholder meeting, subject to continuous service.

Key Dates

Keywords

Instil Bio, TIL, Form 4, SEC filing, stock options, insider transaction, beneficial ownership, director compensation, equity incentive plan